Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
- 1 Introduction
- 2 CSR IN EGYPT: CARING FOR PEOPLE
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 100,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
Medicine has made great progress in the last century. The average life expectancy of people worldwide has doubled in that time, thanks in large measure to the development of innovative treatments for serious diseases.
At Sanofi, we have a clear and resolute line for action: to contribute to the continuous advancement of health. As a company, and as individuals, Sanofi and its talented employees have always striven to advance the cause of health by developing treatments that prevent and treat diseases, while enhancing access to healthcare for the people around the world.
The expertise we have developed along the way has had a profound effect, particularly in the developing world. We have developed the first vaccine for the dengue virus, which infects 390 million people each year, and whose range is expanding due to climate change. Since the beginning of the year, first vaccinations campaigns have started in the Philippines. Thanks to systematic vaccination campaigns, we are close to eradicating polio; while over the last decade, sleeping sickness treatments have saved more than 180,000 lives. In addition, we provide innovative treatments for global killers like diabetes and cardiovascular diseases.
Yet, there is much to be accomplished. A third of the world’s population still has no access to healthcare. And providing health products and services is just one part of the solution to tackle health inequalities that threat human development. As a responsible leader, we must adapt the way we operate to meet our commitment to health. n 2006, Iraqis infected with HIV sued Sanofi and Baxter due to HIV-contaminated haemophilia blood products sold by Merieux in the 1980s. In 2006 the US patents on clopidogrel (Plavix) were challenged when a Canadian generics company, Apotex, filed an Abbreviated New Drug Application under the Hatch-Waxman Act, received FDA approval, and started marketing a generic clopidogrel. While Sanofi-Aventis and its partner on the drug, Bristol Myers Squibb (BMS), were able to get an injunction to stop Apotex from selling the drug, the case became complicated when settlement negotiations fell apart twice - the second time due to an oral agreement made by BMS CEO Peter Dolan that BMS failed to disclose to the Federal Trade Commission during the review of the settlement agreement to ensure that it did not violate antitrust law. When Apotex disclosed the oral agreement to the FTC, the FTC launched an investigation that led to Dolan being fired by BMS.Apotex finally lost on the patent litigation issues after its third appeal was decided in favor of BMS/Sanofi in November 2011; Apotex had to pay ~$442 million in damages and ~$108 million in interest for infringing the patent, which it paid in full by February 2012. Apotex also sued BMS and Sanofi for $3.4 billion for allegedly breaching the settlement agreement, and Apotex lost a jury trial in March 2013
CSR IN EGYPT: CARING FOR PEOPLE
Ensuring occupational health, safety and well-being
Protecting the health and safety of our employees is a key priority for sanofi. Regardless of the nature and type of collaboration (involving Group employees, temporary employees or external service providers), the Group has adopted a policy to assess and control risks.
HSE compliance for subcontractors and suppliers
Issues concerning supplier health, safety, and the environment have been the focus of growing attention in recent years. As a result, the number of actions implemented by industry has also risen considerably.
Working in the pharmaceutical industry, several thousand suppliers and subcontractors are responsible for manufacturing chemical substances that will be used as raw materials or synthesis intermediates. Most companies have set up programs to ensure that these external partners are able to carry out their work in strict compliance with rules concerning health, safety and protection of the environment.
In accordance with the Sanofi Egypt HSE policy, sanofi adopts a constructive attitude of transparency and dialogue toward external partners with respect to health, safety and environmental protection.
Each entity takes into account these issues during operations involving purchasing and outsourcing. The selection of a contractor or supplier includes criteria relating to health, safety and the environment, measured in proportion to the risk incurred based on information exchanged regarding products and processes.
This commitment makes it possible to ensure compliance of the operations performed by our partners. It is one of the key principles of Sanofi Egypt HSE policy.
Rhône-Poulenc began in 1928 as a manufacturer of chemicals, textiles and medicines, and acquired the US company Rorer between 1990 and 1997, the vaccine laboratory Pasteur Mérieux Connaught in 1994 and the British pharmaceuticals company Fisons in 1995 to become a leading industry player worldwide.
Synthélabo was formed in France in 1970 by the merger of Laboratories Dausse (founded in 1834) and Laboratories Robert & Carrière (founded 1899).
Sanofi was founded in 1973 when French oil company Elf Aquitaine acquired the pharmaceutical group Labaz. Its subsequent growth was driven by a combination of international acquisitions and developing new therapies such as the anti-platelet agent Ticlid, its first major product. Innovation remained central, winning Sanofi the prestigious Prix Galien in 1986 for work on the anti-coagulant heparin and in 1987 for Ticlid. Sanofi entered the US market in 1994 with the acquisition of Sterling Winthrop.
Aventis was the result of a 1999 merger of Rhône-Poulenc and Hoechst Marion Roussel, which had boosted its drug development capability by acquiring Roussel-Uclaf in 1974, and merging with the US company Marion Merrell in 1995. Aventis, therefore, had global reach and, with its strong foundation of innovative science, was among the first to invest in the new technologies of genomics, immunology and gene therapy.
Sanofi-aventis was formed in 2004 when Sanofi-Synthélabo (a merger of Sanofi and Synthélabo in 1999) acquired Aventis.
In 2011 sanofi-aventis acquired Genzyme Corporation and at the 2011 Combined Shareholder meeting shareholders approved the change of company name to Sanofi.
Since 2004, Sanofi has developed into a diversified global healthcare company using innovation to meet the needs of patients throughout the world, with recent acquisitions including, Zentiva, Medley, Kendricks, Acambis and Symbion Consumer, as well as Merial in animal health.
Sanofi Fights Bid To Combine EpiPen Suits Against Mylan 
Top 5 Recent Tweets
|August 05, 2022||waynopennyworld||thats what real led me here 4 sure Sanofi Aventis peeps would not be here if this didnt have a huge future TRRI… https://t.co/Ks4YQnR2PT|
|August 01, 2022||LawEconCenter||You can find the full amicus here - signed by Vernon L. Smith, @geoffmanne, @GusHurwitz, @RichardAEpstein, Kenneth… https://t.co/khmhigQZ2K|
|August 02, 2022||OgilvyBot||Sanofi-Aventis. Bored? We'll stick the 'I' into diarrhea.|
|August 01, 2022||LawEconCenter||The 10th Circuit cited the amicus from @LawEconCenter in their decision finding that Sanofi-Aventis had not demonst… https://t.co/ELxwNvtliT|
Top 5 Recent News Headlines
Sanofi recently made a global statement providing new data on our dengue vaccine that helps to further define the population that would best benefit from its protective value. Currently, the World Health Organization and the National Regulatory Authorities in the countries where the vaccine is approved or under regulatory review today are considering this new information to assess the implications for the continued roll-out of the vaccine. http://mediaroom.sanofi.com/striving-to-defeat-dengue-with-effective-vaccines-2/